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Abstract 
Physical Forces from the Extracellular Matrix Influence Breast Cancer 
Cell Response to Doxorubicin 
Marshall Hunter Joyce, PhD 
The University of Texas at Austin, 2018 
Supervisor:  Amy Brock 
Cancer is a complex disease capable of affecting multiple organs and is driven by 
numerous factors. Certain ‘hallmarks of cancer’ have been identified which describe 
biological conditions that lead to tumor development and characteristics that often follow 
tumorigenesis. These hallmarks have been revisited to describe the role that the 
extracellular matrix (ECM) plays in each. Such observations make it evident that the ECM 
is an important factor in tumor initiation, progression, and metastasis and can no longer be 
ignored in the search for a cure. Studies aimed at characterizing the role physical cues play 
in tumor development have considered ligand variety, ligand density, substrate 
composition, and substrate stiffness. These studies frequently utilize hydrogels as a culture 
platform given the biological relevance and diversity achievable through such a platform. 
Though the stiffness of hydrogels can be attenuated at the onset of an experiment, few 
systems are able to alter stiffness once gelation is complete. This makes any study of 
progressive changes in ECM stiffness difficult and largely restricts the study of certain 
temporal aspects of tumor progression in vitro. Recently, a Matrigel-alginate hydrogel 
system has been described whereby progressive modulation of hydrogel stiffness can be 
vii 
achieved using liposomes loaded with gold nanorods and near infrared light. In this study 
we utilize this hydrogel system to thoroughly investigate the role that ECM stiffness has 
on breast cancer response to doxorubicin. We sought to observe how progressive stiffening 
of the ECM affected breast cancer cell response to clinically relevant chemotherapeutics 
in a system that allows for minimal perturbation of cells during the stiffening process. Our 
results showed that breast cancer cells exhibiting a mesenchymal phenotype had a stiffness-
dependent resistance to the chemotherapeutic doxorubicin. Mathematical modeling was 
used to determine reduced growth rate alone was not sufficient to explain this stiffness-
dependent resistance, suggesting an additional mechanism associated with the 
mesenchymal phenotype is responsible. 
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Chapter 1: Introduction1 
1.1 THE EXTRACELLULAR MATRIX 
The extracellular matrix (ECM) encompasses all the non-cellular components of a tissue 
that support and give structure to the cells1. It is a vital component in all animals that functions as 
a scaffold for cells to adhere to and a medium for transmitting biochemical and biomechanical 
cues. The ECM is separated into two domains: the interstitial connective tissue matrix2 and the 
basement membrane3. Interstitial connective tissue matrix fills the interstitial space between cells 
and is composed primarily of collagens I, III, V, VI, VII, XII2; fibronectins4-6; and proteoglycans, 
mostly chondroitin sulfate7,8 and heparin sulfate9,10. The basement membrane is a specialized ECM 
that separates epithelium from mesenchyme, guides cellular differentiation11, stores growth 
factors12, and plays a role in cell proliferation and migration. It is vital for epithelial cells to 
properly orient themselves. Epithelial cells will anchor their basal side to the basement membrane 
with the apical side being exposed to a fluid-filled lumen. The basement membrane is primarily 
composed of type IV collagen, laminin, nidogen/entactin, and perlecan. Collagen13 and laminin14 
are the major structural components, as they are able to independently self-assemble into networks. 
Nidogen/entactin and perlecan further stabilize the basement membrane by binding to both 
collagen and laminin, thus bridging the two networks and increasing structural integrity15-18. 
The early discoveries of the ECM can be attributed to mostly to gross characterization and 
light microscopy. Nageotte and collaborators were able to isolate what we now know to be collagen 
from rat tissue in the 1930’s19. This substance was brought to their attention when they noted its 
ability to reversibly solubilize and reconstitute into fibrils. During this time, the invention of the 
electron microscope20 and advances in x-ray diffraction21 would make it possible for researchers 
to more fully understand the structure of ECM components and how they might interact with one 
1 Portions of this chapter were adapted from M. H. Joyce, S. Allen, L. Suggs and A. Brock, “Novel Nanomaterials 
Enable Biomimetic Models of the Tumor Microenvironment,” Journal of Nanotechnology, vol. 2017, pp. 1-8, 2017. 
M. H. Joyce, S. Allen, L. Suggs and A. Brock wrote this review article. 
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another in vivo. Richard Bear22 studied collagen fibrils using x-ray diffraction and found they had 
a 64 nm repeating period, and this finding was confirmed by Hall et al.23 via electron microscopy. 
Schmitt et al.24 utilized both x-ray diffraction and electron microscopy, as well as chromatography 
to show that collagen molecules could transition from fibrils into bundles they referred to as 
segment long spacings (SLS), and vice-versa. The same year, multiple groups used x-ray 
diffraction patterns of collagen fibrils to refine this model to the triple-chain collagen helix we 
know today25-27. Laminin wasn’t discovered until 1979, and its characterization followed a much 
different path from collagen given the significant advances in technology. Laminin was first 
isolated from the Engelbreth-Holm-Swarm (EHS) sarcoma, a mouse tumor that was shown to 
produce ECM basement membrane28,29. It was identified when researchers found that neutral 
buffers extracted very little type IV collagen from these tumors, but a substantial amount of non-
collagenous proteins. Ion exchange chromatography was used to determine the amino acid 
composition, polyacrylamide gel electrophoresis was used to determine approximate molecular 
weight, and immunofluorescence was used to localize laminin to the basement membrane29. 
The exact composition of the ECM depends on a number of factors that also influence 
resident cell phenotype such as mechanical forces, biochemical signals, oxygen requirements, and 
pH. Such factors vary across species and even across tissue types within species, so the ECM 
composition is highly tailored to the tissue type that it is found in. Tailoring the ECM is one control 
mechanism the tissue as a whole has on regulating local cell phenotype, migration, and 
proliferation30-33. Collagen is the major insoluble fibrous protein in the ECM34, and the main 
structural element of the ECM1, however there are numerous types that help shape the physical 
characteristics of a tissue type. Types I and III collagens have tremendous tensile strength, which 
makes them the ideal components for the ECM of tendons that connect muscle to bone34. On the 
other hand, type II collagen fibrils are smaller in diameter and orient randomly, giving the ECM 
of cartilage tissues their compressibility and resistance to deformations in shape34. These 
differences in ECM composition extend beyond variation in collagen types; the proteoglycan 
profile of skeletal muscle tissue, for example, is dominated by the small leucine-rich proteoglycan 
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family35, whereas chondroitin sulfate proteoglycan constitutes the major population of 
proteoglycans in the central nervous system36. Glycosaminoglycans (GAGs) are the primary 
polysaccharide found in vertebrate ECM, however chitin (poly-N-acetylglucosamine) and 
cellulose are the main polysaccharides found in insect and plant ECM, respectively37. 
ECM composition contributes significantly to the overall physical properties of the tissue, 
including its stiffness, viscoelasticity, and pore size. Table 1.1 shows stiffness measurements of 
various tissue types and illustrates the contribution of ECM to the stiffness of each tissue. The 
measurements listed in Table 1.1 were collected primarily using atomic force microscopy (AFM) 
and magnetic resonance elastography (MRE)38. Atomic force microscopy is a form of scanning 
probe microscopy39 that skims along the surface of a sample and, by tracking the deflection of 
laser light off the probe tip, can apply indentations along a samples and calculate the force required 
to do so and approximately how stiff the material must be to resist that force40. Magnetic resonance 
elastography works by inducing mechanical shear waves into the tissue, imaging with phase-
contrast MRI techniques, and processing the wave images to calculate a measurement of 
stiffness41. Tissue viscoelasticity is dependent on the structural proteins of the ECM, 
crosslinking42,43, folding/unfolding of ECM proteins44,45, and flow of fluid through the ECM43. 
This property is especially important in softer materials and tissues, as compliant samples can lead 
to inaccurate measurements of stiffness when using techniques like nanoindentation46. 
Measurements of the viscoelasticity of ECM or ECM substitutes is typically performed using a 
rheometer to measure shear stresses and strains that are applied to the sample47. The porosity of 
the ECM helps dictate what size molecules and cells can move through the ECM. Since the pore 
size can be as small as a few nanometers, electron microscopy is a method commonly used to 
measure the average pore size and porosity of ECM.  
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1.2 EXTRACELLULAR MATRIX PLAYS CRUCIAL ROLES IN PHYSIOLOGY, DEVELOPMENT, AND 
DISEASE 
During embryogenesis and early development, cells rely on physical cues, chemical 
gradients, and electrical signals for differentiation and morphogenesis. The ECM provides physical 
cues and facilitates chemical signaling during normal tissue development48. This is probably most 
evident in cardiomyocytes and myoepithelial cells lining blood vessels, which are highly sensitive 
to stretch and tension. Myocardial cells have been shown to increase their size and protein 
production upon exposure to cyclical stress, as opposed to myocardial cells that are grown in a 
static environment49. Cyclical stretching of cardiomyocytes induces phosphorylation of pathways 
involved in differentiation and proliferation such as ERK, JNK, FAK, and p38 MAPK50. 
Chondrocytes also require mechanical tension for proper development and maturation. Wong et 
al.51 demonstrated that cyclical tension activates the Cbfa1/MMP-13 pathway and increases 
expression of terminal differentiation hypertrophic markers such as COMP and lubricin. Even 
neurons and glial cells respond to the mechanical properties of the tissue microenvironment to 
maintain normal physiological function52-57. Landmark studies in the field of neuronal 
development have shown how tension along axons and other mechanical cues contribute to 
organization of the nervous system58-60.  
Dysregulation of structure, function, or composition of the ECM contributes to many 
various diseases and conditions61. The mechanical properties of tissues vary widely among 
different physiological and pathological states62,63. Fibronectin has been shown to play a role in 
cardiovascular disease and tumor metastasis64,65. In the liver, hepatic fibrosis will cause stiffening 
of the ECM66,67. Similarly, patients with chronic obstructive pulmonary disease (COPD) have been 
reported to have decreased elastin68-70 and proteoglycans71 with increased collagen content in the 
alveoli, leading to a stiffening of the lung tissue and decreased elasticity. A detailed analysis of the 
ECM composition of COPD patients further showed decreased expression of type I collagen in the 
large and small airways, lower versican fractional area in distal parenchyma regions, and higher 
fractional areas of fibronectin and tenascin in large and small airways72. 
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Tumors are typically stiffer than their surrounding healthy tissue and this is due, in part, to 
increased ECM deposition, ECM remodeling, and increased contractility of cells in the tumor 
microenvironment73-75. Tumor cells also secrete matrix metalloproteases (MMPs)76,77 that break 
down surrounding basement membrane, releasing sequestered growth factors such as vascular 
endothelial growth factor (VEGF)77,78 from the matrix. VEGF promotes the branching growth of 
blood vessels through angiogenesis, which further increases interstitial tissue pressure through 
added cell density. This leads to a positive feedback loop where tumor-associated stiffening causes 
the release of growth factors, which leads to increased interstitial pressure from proliferation, 
angiogenesis, and cellular contractility73,79-81. Similar changes have been observed in ECM of 
mammary tissue progressing through the stages of breast cancer82-88. Healthy mammary gland 
tissue is characterized as have a basement membrane composed of laminins, type IV collagen, 
nidogens, and perlecan with an interstitial ECM composed of fibrillar collagens (types I, III, and 
V), fibronectin, decorin, and biglycan. During cancer progression, MMPs and other ECM 
remodeling enzymes breakdown the basement membrane89 leading to decreased levels of type IV 
collagen83,84 and laminin-11190. The surrounding interstitial ECM gradually stiffens due to 
increased deposition of fibrillar collagen (types I, III, and V) and fibronectin along with elevated 
LOX activity74. Matricellular proteins that promote tumor cell survival including tenascin C, 
periostin, osteopontin, SPARC, and thrombospondin-1 are upregulated91, as are the versican92, 
syndecan-193, and glypican-1 proteoglycans94. These changes in mammary tissue ECM 
composition promote tumor growth and progression, which leads to a positive feedback loop that 
leads to further tissue stiffening and disease progression. 
The difference in stiffness between healthy tissue and tumors may be significant and may 
be detectable by physical palpation. In fact, palpation remains a time-tested diagnostic tool for 
physicians as a means of quickly scanning the body for differences in the mechanical properties 
that would signify healthy or abnormal tissue. It is still used as a standard medical test to detect 
breast tumors95 and liver tumors96. 
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1.3 CELLS SHARE A RECIPROCAL SIGNALING RELATIONSHIP WITH THEIR EXTRACELLULAR 
MATRIX 
The ECM exists in a state of dynamic equilibrium, as cells are constantly breaking down 
components of the ECM and secreting new ECM proteins31. Fibroblasts secrete and organize type 
I and III collagens, elastin, fibronectin, tenascin, hyaluronic acid, decorin, and additional 
proteoglycans to ensure structural integrity of interstitial ECM1. Conversely, cells also produce 
MMPs to break down ECM to facilitate cell migration and the release of growth factors that are 
sequestered in the ECM. Cells and their surrounding ECM are tailor made for one another. For 
example, smooth muscle cells assume an elongated cell shape based on interactions with the αvβ3 
integrin receptor and tenascin-C, which promotes EGF-dependent survival97. Roskelley et al.98 
further describe a dynamic signaling hierarchy that occurs during mammary gland development. 
First they describe how a mammary cell must detach from its rigid substrate to allow for changes 
in cytoskeletal and nuclear architecture. This leads to integrin-dependent biochemical signals 
(FAK phosphorylation, MAP kinase activation, and transient increase in AP1 transcription factor 
activity) which activate ECM-responsive elements such as BCE-1. Signals initiating in the cell 
nucleus are conveyed to the surface membrane where changes to the ECM are executed; this might 
involve increasing MMP production to breakdown ECM or increasing secretion of structural ECM 
proteins. Tumor cells have also been shown to take advantage of this reciprocal relationship 
between cells and ECM. Fullár et al.99 found that cancer-associated fibroblasts (CAFs) produced 
significant amounts of laminin-1 in response to signals sent from cervical cancer cells (CSCC7) 
that predominantly migrated towards and produced integrin receptors (α6β4) for laminin. 
1.4 RESISTANCE TO CHEMOTHERAPEUTIC TREATMENTS 
Breast cancer is the second leading cause of cancer death among women100. It is estimated 
that breast cancer will have seen 268,670 new cases emerge and caused 41,400 deaths in 2018 in 
the U.S. alone100. One of the most challenging aspects of treating cancer is the fact that small 
populations of cancer cells may be resistant treatment and persist after treatment has finished. 
These cells survive the initial round of treatments, continue to proliferate, repopulate the tumor 
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(disease relapse), and may metastasize to other regions. Only 10% of malignant tumor types can 
be eradicated by chemotherapy, leaving the other 90% with varying degrees of improved 
survivability101. Current treatment regimens will usually include administering a cocktail of 
chemotherapeutics to the patient prior to (neoadjuvant) or immediately following (adjuvant) 
surgical resection of the tumor in an attempt to fully eradicate the disease. However, nearly 50% 
of all cancer patients are afflicted with a malignancy that is intrinsically resistant to 
chemotherapeutic treatment101. Most of the remaining half will stop responding to treatment as 
tumor cells acquire resistance to the chemotherapeutics being used. Intrinsically resistant tumor 
cells have pre-existing mutations that confer a survival advantage during initial treatment, whereas 
cells with acquired resistance (also known as therapy-induced resistance) undergo changes in 
response to treatment that ultimately decrease the effectiveness of the drug. A good example of 
intrinsic resistance is seen in tumor cells that carry the BRAF V600E mutation, which renders 
those tumor cells resistant to BRAF inhibitors102,103. Studies that selected for resistant populations 
through progressively increased dosing with topoisomerase II poisons (daunorubicin, doxorubicin, 
melphalan ) showed that the surviving cells overexpressed the multi-drug resistance 1 (MDR1) 
gene which increased cell resistance through P-170-mediated MDR104-106. The molecular 
mechanisms behind cancer cell resistance to chemotherapeutic treatment include transporter 
pumps, activation of oncogenes, suppression of tumor suppressor genes, mitochondrial alteration, 
DNA repair, autophagy, epithelial-mesenchymal transition (EMT), cancer stemness, and 
exosomes107-109. In the present study, we focus primarily on the chemotherapeutic drug, 
doxorubicin (trade name Adriamycin®). This anthracycline functions by disrupting 
topoisomerase-II-mediated DNA repair110,111, generating free radicals to damage cellular 
membranes112,113, and inducing histone eviction114. It has proved useful as a broad-spectrum 
chemotherapeutic in neoadjuvant breast tumor therapies, but it is known to induce resistant cells 
that can cause disease relapse. Mechanisms of doxorubicin resistance may involve ABCB1 
(MDR1, Pgp)115, ABCC1 (MRP1)116-118, ABCC2118, ABCC3118, ABCG2, and RALBP1119 
transporters, as well as amplification of TOP2A120-122. Another chemotherapeutic agent used in 
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this study is paclitaxel (trade name Taxol®), a member of the taxane class. This is a microtubule 
stabilizer that kills cancer cells by polymerizing and stabilizing mitotic spindles in dividing cells, 
thus preventing them from clearing the mitotic checkpoint123. Resistance to paclitaxel has been 
shown to arise through a variety of mechanisms. The mechanisms that are most well-studied 
include alterations to expression of IL-6 and IL-8 cytokines, alterations in β-tubulin, alterations in 
genes involved in apoptosis (BCL-2, BCL-XL, BAX, BAD, and p53), and overexpression of P-
glycoprotein124. Many other mechanisms of paclitaxel resistance have been proposed as well 
including changes in fibroblastic growth factors125, increased expression of transmembrane 
receptors126,127, increased expression of adhesion molecules128, increased expression of certain cell 
signaling molecules128-134, increased expression of nuclear proteins134-136, and the switch from 
apoptotic to autophagic cell death137. This list is by no means exhaustive, but illustrates the 
complex nature of treating cancer patients with modern chemotherapeutics.  
1.5 THE EXTRACELLULAR MATRIX INFLUENCES HOW TUMOR CELLS WILL RESPOND TO 
CHEMOTHERAPEUTIC TREATMENT 
Cancer is a complex disease capable of affecting multiple organs and is driven by numerous 
factors. Hanahan and Weinberg138,139 have summarized and defined certain ‘hallmarks of cancer’ 
which describe biological conditions that lead to tumor development and characteristics that often 
follow tumorigenesis. Pickup et al.140 revisited these hallmarks and described the role that the 
extracellular matrix (ECM) plays in each. Such observations make it evident that the ECM is an 
important factor in tumor initiation, progression, and metastasis and can no longer be ignored in 
the search for a cure. Studies aimed at characterizing the role physical cues play in tumor 
development have considered ligand variety, ligand density, substrate composition, and substrate 
stiffness141-147. More recent studies are focusing on understanding how the physical cues from the 
microenvironment affect how cancer cells will respond to chemotherapeutic treatment. Shin & 
Mooney144 investigated how ECM stiffness would affect chemosensitivity of myeloid leukemia 
cells lines by culturing them within alginate hydrogels that not only varied in stiffness, but in 
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functionalizing peptide. What they were able to show was that the myeloid leukemia cell lines 
challenged with varying chemotherapeutics would fall into one of three categories: ligand 
sensitive, ligand and matrix stiffness sensitive, or mechanics independent. Zustiak et al.148 cultured 
multiple cancer cell lines on top of collagen-coated polyacrylamide hydrogels that ranged from 1 
– 100 kPa in stiffness. These samples were treated with paclitaxel to observe how ECM stiffness 
would modulate drug sensitivity. Their results showed only found HeLa and SY5Y cell lines to 
have a stiffness-dependent resistance to paclitaxel out of the 10 cell lines tested, however their 
study was limited in that the cells were cultured on top of the hydrogels and not embedded within 
them. Rice et al.149 performed a very similar study with pancreatic ductal adenocarcinoma (PDAC) 
cell lines cultured on 1, 4, and 25 kPa polyacrylamide hydrogels. In their study, they found that 
the PDAC cell lines they used had a stiffness-dependent increase in resistance to paclitaxel. To 
uncover the mechanism behind the observed stiffness-dependent resistance, they measured total 
expression of vimentin and nuclear localization of YAP/TAZ. Their results showed that the PDAC 
cells they cultured on stiffer hydrogels increased expression of vimentin and had higher levels of 
nuclear localized YAP/TAZ.  
YAP (yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding 
motif) are functionally similar transcriptional co-activators capable of inducing EMT150. As the 
Hippo pathway effector, YAP has been shown to promote metastasis through its TEAD-interaction 
domain151 and upregulation of EGF receptor152 (Fig 1.1). LATS1/2 kinases are members of the 
Hippo pathway that will phosphorylate, and thus inhibit, YAP153,154. When YAP is phosphorylated, 
it will remain in the cytoplasm of the cell where it will eventually be marked for proteasome 
degradation. Once translocated to the nucleus, however, it can perform its role as a transcriptional 
co-activator that regulates organ size, cell proliferation, and EMT. YAP has been shown to drive 
these effects through targeting of ABCB1, ANKRD, CAT, GPATCH4, LMNB2, PTGS2, TXN, 
WSB2, and more specifically AXL, CDKN2C, CTGF, CYR61, DAB2, DLC1, TSTL1, LHFP, 
SDPR, SERPINE1, SLIT2, TGFB2, and THBS1 in breast tumor samples155,156. 
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Tissue Elastic Modulus (E, Pa) References 
Brain, white matter (~2.25) x 102 Christ et al.155 
Brain, gray matter (~3.4) x 102 Christ et al.155 










Endothelium, aortic (0.1 – 2) x 103 Sato et al. 160 









Liver (12.88) x 103 Tay et al.161 






Articular cartilage (0.4 – 200) x 106 Nemir and West164 
Bone (0.008 – 40) x 109 Nemir and West164 
Table 1.1 – ECM stiffness varies across tissue types. Tissue stiffness measurements acquired 
from numerous methods are summarized here according to tissue type. The values 
displayed represent the tissue’s measured Young’s Modulus (E). Stiffness of tissue 
types varies drastically across the body to facilitate the differing physiological 




Fig. 1.1 – Canonical YAP pathway.  YAP is a component of the Hippo signaling pathway. 
Phosphorylated (red) YAP remains in the cell cytoplasm where it is inactive. YAP 
is ubiquitinated (yellow) by β-TrCP which signals it for proteasome degradation. If 
Lats1/2 is inhibited and YAP remains unphosphorylated, it translocates to the 
nucleus where it acts as a transcriptional co-activator. 
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Chapter 2: Characterization of Breast Cancer Cell Resistance to 
Chemotherapeutics in Alginate Hydrogels2 
2.1 INTRODUCTION 
The extracellular matrix (ECM) plays a critical role in the control of cell processes 
including cell survival, proliferation and apoptosis1-3. Cancer cells as well as normal cells integrate 
signals from ECM and may initiate different signaling programs in response to 
microenvironmental cues4-6.  Understanding the contribution of mechanical signals from the 3D 
ECM in the tumor microenvironment is therefore important for predicting tumor progression and 
response to therapeutics.  
There are many methods and platforms that can be used to grow and maintain cells as 3D 
cultures in vitro. One such method is to harvest matrix proteins such as collagens, laminins, or 
fibrins to construct a scaffold on which cells can grow. The primary advantage of using collagen 
and other native matrix proteins is their ability to closely mimic the fibril formation and a 
viscoelastic properties of their native environment7. Provenzano et al.8 made use of this approach 
in studies of mouse mammary carcinoma cells cultured in dense collagen hydrogels to simulate 
mammographically dense breast tissue, a major risk factor for developing breast carcinomas9-12. 
However, this study also highlights one of the difficulties of using collagen hydrogels, namely that 
pure collagen hydrogels are typically of low stiffness (< 1 kPa) and stiffening collagen hydrogels 
comes at the cost of increasing overall collagen density or requires extensive chemical 
crosslinking.  
Matrigel is a commercially available basement membrane extract consisting primarily of 
laminin, type IV collagen, entactin, and various growth factors13. The milieu of native matrix 
components and growth factors make it an appealing option for hydrogel cultures. However, 
Matrigel preparations are produced from basement membrane extracts from Engelbreth-Holm-
                                                 
2 Portions of this chapter were adapted from M. H. Joyce, C. Lu, E. R. James, R. Hegab, S. C. Allen, L. J. Suggs and 
A. Brock, "Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to 
Doxorubicin," Front Oncol, vol. 8, p. 337, 2018. A. B. and M. J. were responsible for the planning of the study and 
writing of the manuscript; C. L., E. J., M. J., R. H., and S. A.conducted the experiments; all authors were involved 
with the analysis of the manuscript. 
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Swarm mouse sarcoma tumors, meaning they are of tumorigenic origin and subject to significant 
batch-to-batch variation. This is an important factor for technologies and studies that require Good 
Manufacturing Processes (GMP) enforced by the Federal Drug Administration (FDA); it may also 
impact many studies that require a higher degree of precision in matrix composition.  
Hyaluronic acid (HA) also falls in the native matrix component category. It is an anionic 
non-sulfated glycosaminoglycan distributed throughout connective, epithelial, and neural tissues. 
HA is an essential component of vertebrae ECM during growth, repair, and neoplasia14-16. It can 
be isolated from animal tissues or produced through microbial fermentation in Escherichia coli. 
Unmodified HA is not compatible with integrin-mediated cell adhesion, but rather facilitates cell 
adhesion through cell surface markers such as CD44 and CD16817. However, HA can be modified 
to present functional groups that allow for a broad range of crosslinking chemistries and can be 
further processed to form films (2D) or hydrogels (3D)18. Researchers have made use of this 
flexibility to investigate cellular mechanotransduction19,20. 
Non-native biological materials have also been shown to be suitable for mimicking ECM. 
Shin and Mooney21 have previously used alginate-based hydrogels to mimic matrix stiffness 
conditions that would be physiologically relevant for myeloid leukemia cells. Using ionic cross-
linking, it was feasible to produce hydrogels that model a range of microenvironments, from stiff 
bone marrow (Young’s modulus E = 3 kPa) to low shear blood (E = 40 cP). The alginate-based 
system proved ideal for these conditions, as the stiffness of hydrogel cultures could be tuned by 
including increasing concentrations of calcium sulfate to achieve stiffer hydrogels. In these studies, 
hydrogels as soft as E = 75 Pa could be fabricated with the cross-linking agent (calcium sulfate), 
and fluid cultures (E = 40 cP) could be maintained when no cross-linking agent was added. This 
platform allowed Shin and Mooney to study matrix mechanics of myeloid leukemias subtypes in 
ECM mimicking diverse in vivo environments.  
Synthetic polymers can also be used to facilitate 3D cultures. Polyethylene glycol (PEG), 
acrylamide, and custom polypeptides are examples of polymers that can be used to create 
hydrogels. Zustiak et al.22 used collagen-coated polyacrylamide hydrogels to form hydrogels from 
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E = 1 kPa – 100 kPa. These hydrogels provide a very broad range of potential stiffness making 
them ideal for testing stiffness-dependence across many orders of magnitude. However, they must 
be coated with peptides or coupled with other matrix proteins to promote cell adhesion, and they 
are not a good representation of the fibrous networks that make up the ECM in vivo.  
In this chapter, we utilize an alginate hydrogel model developed by Stowers et al.23, to 
culture breast carcinoma cells in engineered microenvironments with specific stiffness properties. 
We investigate whether ECM stiffness in these hydrogels affects cell response to cytotoxic 
chemotherapeutic treatments.  We explore two types of therapeutics, with different mechanisms 
of action, and compare their action in multiple human breast carcinoma and mouse mammary 
carcinoma models.  
2.2 MATERIALS AND METHODS 
2.2.1 Cell culture 
MCF7 cells were cultured in Minimum Essential Media (MEM, Life Technologies, REF: 
11095-080, 89%) supplemented with Fetal Bovine Serum (FBS, Life Technologies, REF: 10437-
028, 10%) and Penicillin/Streptomycin (P/S, Life Technologies, REF: 15070-063, 1%). Py2T cells 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies, REF: 10569-
010, 89%) supplemented with FBS (Life Technologies, REF: 10437-028, 10%) and P/S (Life 
Technologies, REF: 15070-063, 1%). MDA-MB-231, TMEC, and M6 cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technologies, REF: 10569-010, 94%) 
supplemented with FBS (Life Technologies, REF: 10437-028 5%) and P/S (Life Technologies, 
REF: 15070-063, 1%). All cultures maintained in a tissue culture incubator set to 37 °C with 5% 
CO2. For 2D cultures, cells were grown as a monolayer in 12- (TrueLine, TR5000) or 96-well 
(Falcon, REF: 353072) plates. Studies done in 12-well plates have an n = 3 for each condition, 
while studies using 96-well plates have an n = 5 for each condition. 
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2.2.2 Hydrogel preparation 
The system described in these studies is a Matrigel-alginate based system. Hydrogels were 
prepared by mixing the following ingredients in the order described with thorough mixing after 
addition of each ingredient: 4% alginate (1.6% final concentration, 40% total volume; ProNova 
UP MVG), 5 – 20 mM calcium carbonate (5% total volume), 100 mM NaCl + 1mM HEPES buffer 
(20% total volume), cells (5% total volume), 10 – 40 mM D-(+)-Gluconic acid δ-lactone (5% total 
volume), and Matrigel (25% total volume; VWR International). Once mixed, 50 µL of the gel 
solution was pipetted into each well of a 96-well plate and placed in an incubator (37 °C, 5% CO2) 
for one hour to promote gelation. After gelation, 100 µL of media was added to each sample and 
placed back in an incubator. Optimal cell seeding density was found to be within the range of 
8,000,000 cells/mL to 16,000,000 cells/mL; this seeding density ensured a sufficient amount of 
cells were cultured for data analysis without overcrowding the available growth area within 
hydrogels. For a 50 µL hydrogel this equates to approximately 25,000 to 50,000 cells per gel, 
respectively. Each condition will have an n = 3. 
2.2.3 Rheometry 
To determine hydrogel stiffness, a hydrogel solution was prepared following the protocol 
outlined in section 2.2.2, and approximately 50 µL of hydrogel solution was pipetted into an 8 mm 
diameter PDMS mold. Samples were then incubated overnight in a tissue culture incubator (37°C, 
5% CO2) before being measured on a Physica MCR 101 Rheometer using an 8 mm geometry 
(Anton Paar, Cat.#: 5681). Frequency sweep measurements were taken from 0.05 rad/s to 500 rad/s 
using Rheoplus (v3.40) software with 5% initial strain. 
2.2.4 Dosing with chemotherapeutics 
Samples were exposed to doxorubicin (Sigma-Aldrich, Cat.#: D1515) or paclitaxel 
(Sigma-Aldrich, Cat.#: T7402) for 48 h. A broad range (1 nM – 200 µM) of doses was used to 
determine the drug sensitivity. 
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2.2.5 Isolation of cells from hydrogels 
To extract the cells cultured in hydrogels for analysis, each 50 µL gel was soaked in 100 
µL of 50 mM sodium citrate (Fisher Scientific, Cat#: BP327) for 15 m at room temperature. Gels 
were then mechanically disrupted by pipetting until the alginate dissolved to a liquid solution. 
Each sample was transferred to a microcentrifuge tube and centrifuged at 600 x g for 10 m to 
pellet. 
2.2.6 Measuring viability 
Viability measures was assessed using acridine orange/propidium iodide (AOPI, 
Nexcelom, Cat#: CS2-0106) stain and MTS reagent (Promega, REF: G3580). Samples treated with 
AOPI were pelleted, resuspended in AccuMAX (Innovative Cell Technologies, Cat.#: AM-105), 
and mixed 1:1 with AOPI stain. Samples were then assayed using a Nexcelom Cellometer Vision. 
MTS assays were performed following the manufacturer’s instructions. Briefly, all cell media was 
removed and replaced with MTS reagent mixed with media at 1:6 ratio, or 20 µL of MTS reagent 
with 100 µL of cell media per well of a 96-well plate. Samples were then incubated at 37 °C (5% 
CO2) for 1 – 2 h before reading their absorbance at 490 nm on a plate-reader. The data gathered 
from both cell viability assays was fit to a sigmoid function in Microsoft Excel and used to 
calculate drug sensitivity, as measured by LD50 value. 
2.3 RESULTS 
2.3.1 An alginate hydrogel platform can be used to make ECM models of varying stiffness 
This study sought to investigate how the ECM stiffness might affect breast cancer cell 
response to chemotherapeutic treatment. To this end, we employed an alginate hydrogel model 
developed by Stowers et al.23. This system was chosen because of the broad range of achievable 
stiffness, uniformity of stiffness throughout the hydrogel, ability to dynamically tune hydrogel 
stiffness (discussed in Chapter 3), and unique ability to isolate the effects of ECM stiffness on 
cells. 
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Stowers et al.23 have shown the capability of this system to form hydrogels as soft as 40 Pa 
and as stiff as 20,000 Pa. The stiffness of this hydrogel system is driven by ionic calcium (Ca2+) 
cross-linking G-blocks on alginate polymers. As additional cross-links are formed, the hydrogel 
will become progressively stiffer. The binding affinity of ionic calcium (Ca2+) to these G-blocks 
is high enough24 to cause almost immediate cross-linking. Attempting to mix ionic calcium (Ca2+) 
with alginate will result in poor diffusion of calcium through the alginate and cause highly 
localized cross-linking. This system instead uses calcium carbonate (CaCO3), which prevents 
immediate cross-linking by keeping ionic calcium (Ca2+) bound to a carbonate (CO3) molecule. 
To achieve cross-linking, glucono-δ-lactone (GDL) is added to the mixture with calcium carbonate 
and alginate. GDL is pH neutral, but hydrolyses in water to gluconic acid, which is subsequently 
buffered by the carbonate (CO3) from the calcium carbonate (CaCO3), thus allowing ionic calcium 
(Ca2+) to bind to alginate G-blocks and form cross-links. This extends the cross-linking process 
such that it occurs over the span of hours rather than seconds, thus allowing gelation to occur 
evenly across the hydrogel. 
Alginate is the major contributing factor to the hydrogel stiffness in this system, however 
alginate is bioinert25 so Matrigel was added to provide cells with a substrate for the formation of 
cell-matrix adhesions and attachment sites. In this approach, cells are unable to directly rearrange 
the hydrogel and alter its stiffness. Such a system allowed us to further isolate the effects of 
stiffness on breast cancer cell resistance with limited dependence on cell adhesion type.  
Hydrogels were prepared with 5 – 20 mM calcium carbonate and oscillatory shear stress 
rheometry was used to measure hydrogel stiffness. To collect stress and strain measurements, a 
hydrogel solution was prepared following the protocol outlined in section 2.2.2. Briefly, 
approximately 50 µL of hydrogel solution was pipetted into an 8 mm diameter PDMS mold. 
Samples were then incubated overnight in a tissue culture incubator (37°C, 5% CO2) before being 
measured on a Physica MCR 101 Rheometer using an 8 mm geometry (Anton Paar, Cat.#: 5681). 
Frequency sweep measurements were taken from 0.05 rad/s to 500 rad/s using Rheoplus (v3.40) 
software with 5% initial strain. The elastic modulus was calculated for each frequency measured 
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within this range. Our results show that we were able to make gels ranging from 450 – 2,000 Pa 
(5 mM = 228 Pa, n = 3; 10 mM = 910 Pa, n = 1; 15 mM = 1,368, n = 8; 20 mM = 1,958 Pa, n = 5; 
Fig. 2.1a) by varying the concentration of calcium carbonate added to the initial gel mixture.  
2.3.2 Characterization of mammary epithelial carcinoma cells to chemotherapeutic 
response in monolayer cultures 
We began our study by challenging breast cancer cell lines with two clinically relevant 
chemotherapeutics – doxorubicin and paclitaxel. MDA-MB-231 and MCF7 cells were cultured as 
a monolayer on tissue culture plastic (2D) and challenged with each drug as a single agent (Fig. 
2.1b). After 48 h exposure the chemotherapeutic was removed and replaced with MTS reagent 
mixed into culture medium at a 1:6 ratio. Samples were incubated at 37C for 2 h, to allow for 
sufficient metabolism of the MTS reagent, and immediately placed on a plate-reader to measure 
490 nm absorbance. These readings were used to calculate cell viability and fit to a sigmoidal 
function to determine the 50% lethal dose (LD50) for each drug-cell combination. The results 
outlined in Fig. 2.2 show that MDA-MB-231 cells were more resistant to doxorubicin (LD50 = 
26.6 µM, Fig. 2.2a) than paclitaxel (LD50 = 94 nM, Fig. 2.2b). MCF7 cells showed a similar 
response with cells being more resistant to doxorubicin (LD50 = 4.4 µM, Fig. 2.2c) than paclitaxel 
(LD50 = 126 nM, Fig. 2.2d).  
Given that these cells lines had similar responses to paclitaxel but not doxorubicin when 
cultured as monolayers (2D), we expanded our study to evaluate the response of additional cell 
lines to doxorubicin (Fig. 2.3). TMEC, M6, M6c, and Py2T cell lines were all cultured as a 
monolayer and challenged for 48 h with doxorubicin. We observed that the MDA-MB-231 and 
Py2T cell lines had a significant advantage over the MCF7, M6, and M6c cell lines when exposed 
to doxorubicin.  
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2.3.3 Characterization of mammary epithelial carcinoma cells to chemotherapeutic 
response in alginate hydrogel cultures 
Our experiments with monolayer cultures have shown that mammary epithelial carcinoma 
cell lines can have differing responses to treatment with doxorubicin. It has previously been shown 
that growing cells in 3D cultures can increase their resistance to chemotherapeutic drugs26-28. We 
sought to explore this with mammary epithelial carcinoma cell lines cultured in the previously 
described alginate hydrogel system. Samples were cultured for six days in either 450 Pa (Fig. 2.4) 
or 2,000 Pa (Fig. 2.5) hydrogels before treatment with doxorubicin; this was done to allow cultures 
plenty of time to form microstructures before exposure to treatment. Our goal was to determine if 
cells grown in 3D cultures would respond differently to the chemotherapeutics, and if so, to 
quantify these differences. We observed that chemoresistance of MDA-MB-231 cells to 
doxorubicin was 3-fold higher in the stiff ECM environment (LD50 = 10 µM in 450Pa hydrogel 
cultures vs. LD50 = 32 µM in 2,000Pa cultures; p = 0.002; Fig. 2.6a,c). MCF7 cells did not display 
any significant (p = 0.134; Fig. 2.6b,d) differences in resistance across substrates of increasing 
stiffness. 
2.3.4 Acute responses to changes in ECM stiffness increase resistance to doxorubicin 
Following our experiments that showed differing responses of mammary carcinoma cell 
lines to doxorubicin in alginate hydrogels, we questioned if the time a cell was exposed to their 
ECM would affect their response to treatment with doxorubicin. Our hypothesis was that cells 
exposed to stiffer ECM for longer would have increased resistance to doxorubicin. To test this 
hypothesis, we cultured MDA-MB-231 (Fig. 2.7a) and MCF7 (Fig. 2.7b) cells in 450 Pa or 2,000 
Pa alginate hydrogels for 4 (3 days + 24 h), 6 (3 days + 72 h), or 8 (3 days + 120 h) days before 
challenging them with a 48 h exposure to doxorubicin.  
Our results showed that MDA-MB-231 cells cultured in either 450 Pa or 2,000 Pa for 4 
days had no significant difference in resistance to doxorubicin (p = 0.822, Fig. 2.7a). However, 
after 6 days (p = 0.002, Fig. 2.7a) and 8 days (p = 0.0005, Fig. 2.7a) MDA-MB-231 cells cultured 
in 2,000 Pa hydrogels showed an increase in resistance to doxorubicin compared to similar cultures 
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in 450 Pa hydrogels. MCF7 cells also showed no significant difference in doxorubicin resistance 
at 4 days (p = 0.575, Fig. 2.7b), 6 days (p = 0.134, Fig. 2.7b), or 8 days (p = 0.333, Fig. 2.7b) 
when comparing 450 Pa cultures to 2,000 Pa cultures. However, there was a significant decrease 
in resistance for 450 Pa cultures (p = 0.001, Fig. 2.7b) and 2,000 Pa cultures (p = 0.046, Fig. 2.7b) 
between the 4 day and 6 day time-point. No significant difference was found between 450 Pa 
cultures (p = 0.064, Fig. 2.7b) and 2,000 Pa cultures (p = 0.965, Fig. 2.7b) between the 6 day and 
8 day time-point. 
Viability assays were performed on cells that were cultured in 450 Pa or 2,000 Pa hydrogels 
at 48 h post-seeding and 1 week post-seeding (Fig. 2.8a). The results were compared to similar 
cells grown on tissue culture plastic, and we found that the total viability was similar for both 
MDA-MB-231 and MCF7 cells grown in all conditions. The culture media of these samples was 
also collected and measured for pH at the same time as viability testing (Fig. 2.8b). We found all 
pH measures to be within acceptable ranges given the values of the 2D (control) samples and 
previous findings in the literature stating that a malignant tumor’s microenvironment can range 
from pH 6.5 – 6.929. 
2.4 DISCUSSION 
Using the alginate hydrogel model described by Stowers et al.23, we optimized conditions 
to generate hydrogels mimicking the ECM stiffness of biologically healthy (~450 Pa) to early stage 
breast tumors (~2,000 Pa)30. We used this experimental model to determine how ECM mimicking 
both normal and early stage tumor tissue affects mammary epithelial carcinoma cell response to 
treatment with chemotherapeutics. Initially, we challenged samples with doxorubicin and 
paclitaxel. Doxorubicin, also known by the trade name Adriamycin, is a common 
chemotherapeutic used to treat neoadjuvant breast cancer. It works by intercalating into DNA and 
inhibiting progression of topoisomerase II after it has broken the DNA double helix for 
replication31. This prevents the DNA strands from resealing, thereby stopping DNA replication 
and ultimately leading to cell death after accumulation of enough unrepaired fragments. Paclitaxel 
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(sold under the trade name Taxol) is a member of the taxane family of drugs which work by 
disrupting microtubule function32. Microtubules in the mitotic spindle are normally highly 
dynamic, growing and shrinking to facilitate segregation of chromosomes to daughter cells during 
mitosis33. Paclitaxel functions as a microtubule-stabilizing agent, binding to β-tubulin near the M 
loop and increasing affinity for tubulin molecules, ultimately suppressing microtubule 
dynamics34,35. It has been shown to cause cell death by trapping cells in the metaphase/anaphase 
transition of mitosis, and thus acts preferentially on cancer cells due to their increased mitotic 
activity36,37.  
Our results showed very similar LD50s for both MDA-MB-231 and MCF7 cells to 
paclitaxel in 2D cultures, but MDA-MB-231 cells had a 6-fold higher LD50 to doxorubicin 
compared to MCF7 cells. The differing response of these two mammary epithelial carcinoma lines 
to the same drug led us to challenge a panel of mammary epithelial carcinoma lines. This panel of 
cells was cultured both as monolayers (2D) and in hydrogels (3D) and challenged with 
doxorubicin. We found that cells displaying a mesenchymal phenotype (MDA-MB-231, Py2T-
LT, TMEC) showed a stiffness-dependent increase in resistance to doxorubicin, whereas cell types 
displaying epithelial phenotypes (MCF7, M6, M6c) did not. This finding is similar to myeloid 
leukemia subtypes described by Shin & Mooney38. They cultured two myeloid leukemia cell lines 
in alginate hydrogels of varying stiffness and functionalized with varying ligands and proceeded 
to challenge cultures with chemotherapeutics commonly used to treat myeloid leukemia. Their 
results showed three subtypes of myeloid leukemia – class I being cells that were ligand sensitive, 
class II being cells that were ligand and matrix stiffness sensitive, and class III being cells that 
were mechanics independent. Our results indicate that the mesenchymal lines we tested would fall 
under the class II subtype, with the epithelial lines falling under the class III subtype. This is further 
supported by Lovitt et al.39 who showed in their 2018 study that functional inhibition of β1-integrin 
signaling in 3D cultures of MDA-MB-231 cells has a dose-dependent increase in sensitivity to 
doxorubicin.  
 35 
We next sought to determine if the duration of exposure to ECM stiffness would affect 
resistance to doxorubicin. By culturing cells for varying periods of time in defined ECM 
environments, we explored the temporal dynamics of ECM-stiffness mediated responses. Our 
results indicate that there is an acute response to ECM changes, but this response levels out after 
approximately 4 days in the hydrogel. This area is currently understudied, but is an important 
consideration when screening for drug sensitivity or efficacy. 
2.5 CONCLUSIONS 
Here we have shown that mammary epithelial carcinoma cell lines will respond differently 
when cultured in hydrogels (3D) as opposed to monolayers. Our results shed light on the 
importance of ECM stiffness and duration of exposure to ECM stiffness when evaluating drug 
sensitivities of mammary epithelial carcinoma cells. We believe that giving more attention to ECM 
stiffness and exposure to ECM stiffness prior to treatment will lead to more accurate simulations 






Fig. 2.1 – Cells were cultured in hydrogels of varying stiffness before treatment with 
doxorubicin. a). Hydrogel stiffness was determined by calculating Young’s 
modulus from frequency sweep measurements obtained from a rheometer. Error 
bars represent a 95% confidence interval as determined by a Student’s t-test 
distribution. The experimental protocol is outlined in b). Briefly, cells were seeded 
onto tissue culture plastic or into hydrogels that ranged in stiffness from 450 to 
2,000 Pa. After 6 days in culture, samples were exposed to doxorubicin for 48h and 




Fig. 2.2 – Cells were cultured as a 2D monolayer and exposed to doxorubicin or paclitaxel. 
MDA-MB-231 and MCF7 cells were cultured as a 2D monolayer and exposed to 
doxorubicin or paclitaxel for 48 h. a) MDA-MB-231 cultures were found to be 
more resistant to doxorubicin (LD50 = 26.6 µM) than b) paclitaxel (LD50 = 94 
nM). c) MCF7 cultures were also found to be more resistant to doxorubicin (LD50 
= 4.4 µM) than similar d) MCF7 cultures treated with paclitaxel (LD50 = 126 nM). 
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Fig. 2.3 – Additional cell lines were cultured as a 2D monolayer and challenged with 
doxorubicin. Additional mammary epithelial carcinoma cell lines were cultured as 
2D monolayers and exposed to doxorubicin for 24 and 48 h before assaying for cell 
viability. MDA-MB-231 and Py2T cell lines were found to be more resistant to 
doxorubicin than the TMEC, M6, or M6c cell lines. 
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Fig. 2.4 – Dose response curves of a) MDA-MB-231, b) MCF7, c) M6, d) M6c, e) TMEC, f) 
Py2T, g) Py2T-LT following 48h exposure to Doxorubicin. All cells were cultured 
in 450 Pa alginate-Matrigel hydrogels for 8 days before being exposed to 




Fig. 2.5 – Dose response curves of a) MDA-MB-231, b) MCF7, c) M6, d) M6c, e) TMEC, f) 
Py2T, g) Py2T-LT following 48h exposure to Doxorubicin. All cells were cultured 
in 2,000 Pa alginate-Matrigel hydrogels for 8 days before Doxorubicin exposure. 
Live and Dead cells were counted using a Nexcelom Cellometer with AOPI stain. 
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Fig. 2.6 – 231 cells have a stiffness-dependent resistance to doxorubicin. Dose response 
curves of 231 and MCF7 cells cultured in a,b) 450 Pa hydrogel, c,d) 2,000 Pa 
hydrogel, and e,f) 2D monolayer following 48h exposure to Doxorubicin. Percent 
cell death was determined by staining samples with AOPI and counting live cells 
using a Nexcelom Cellometer. 
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Fig. 2.7 – Shorter acclimation time gives temporary increase in doxorubicin resistance. 
LD50 values of a) MDA-MB-231 and b) MCF7 cells cultured in 450 Pa hydrogel 
or 2,000 Pa hydrogel for 24, 72, or 120 h before a 48 h exposure to doxorubicin. 
Percent cell death was determined by staining samples with AOPI and counting live 
cells using a Nexcelom Cellometer. 
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Fig. 2.8 – Inclusion of D-(+)-Gluconic acid δ-lactone in hydrogel mixture does not adversely 
affect cell viability. Cells were cultured as a monolayer (2D) on tissue culture 
plastic with culture media supplemented with concentrations of calcium carbonate 
and D-(+)-Gluconic acid δ-lactone equal to those found in 450 Pa and 2,000 Pa 
hydrogel mixtures. Samples were seeded with the supplemented media and 
subsequently fed with normal culture media every other day for the remainder of 
the experiment to mimic the conditions that cells seeded in hydrogels would be 
exposed to.  
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After 5 days in culture, a) cell viability was assayed using acridine orange/propidium iodide 
(AOPI) staining, and b) the media was removed from samples to measure pH 
values. Estrella et al.40 notes that the pH of a malignant tumor’s microenvironment 
can range for pH 6.5 – 6.9. MCF10A cells cultured in presence of the 2,000 Pa 
hydrogel mixture conditions are the only samples to drop below this pH value 
causing almost complete cell death. The remaining MCF7 and 231 cell lines 
showed only slight deviations in pH from control conditions (normal culture media 
for the duration of the experiment), though all of these values fall within an 
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Chapter 3: Characterization of Breast Cancer Cell Response to 
Chemotherapeutics in Dynamic Stiffened Hydrogels3 
3.1 INTRODUCTION 
The ECM is a major component of the cellular microenvironment that facilitates many 
basic cellular functions1 due to its dynamic and transmutable nature2. Cells alter their surrounding 
ECM by changing its composition, through synthesis or degradation of ECM components, or 
architecture, through cross-linking via covalent and noncovalent modifications2. Synthesis of 
ECM components occurs locally. For example, in developing mammary glands, the fibroblasts 
surrounding epithelium will synthesize and deposit collagen I, one of the most abundant ECM 
proteins in mammary gland tissue3. Degradation of ECM components is largely directed by the 
matrix metalloproteinases (MMPs)4,5 with help from adamalysins6-9, meprins10, Ser proteases11,12, 
cathepsins13, heparanases4, and sulphatases4. Cells will also align collagen fibers and other 
structural ECM components through integrin-ECM interactions. It is this interplay of ECM 
degradation, synthesis, and rearrangement that maintains the ECM in a dynamic state and forms 
the basis for a reciprocal relationship between cells and the matrix microenvironment. 
Numerous diverse experimental approaches have been developed to recreate specific 
aspects of the ever-changing ECM. Vincent et al.14 describe a method whereby cells are seeded on 
a coverslip island in the middle of a PDMS hydrogel to simulate a change in substrate stiffness 
and composition. During preparation of the hydrogel, the coverslip is placed on top of the partially 
gelled PDMS, allowing a small amount of PDMS to creep over the edge of the coverslip and form 
an interface between the glass and hydrogel14,15. This enabled the researchers to study how cells 
respond to changes in substrate stiffness and the cellular mechanics that are involved with these 
processes. 
                                                 
3 Portions of this chapter were adapted from M. H. Joyce, C. Lu, E. R. James, R. Hegab, S. C. Allen, L. J. Suggs and 
A. Brock, "Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to 
Doxorubicin," Front Oncol, vol. 8, p. 337, 2018. A. B. and M. J. were responsible for the planning of the study and 
writing of the manuscript; C. L., E. J., M. J., R. H., and S. A.conducted the experiments; all authors were involved 
with the analysis of the manuscript. 
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Guvendiren & Burdick16 developed a methacrylated hyaluronic acid (MeHA) hydrogel 
system capable of dynamically stiffening through UV irradiation. This system allows for the initial 
formation of a hydrogel through addition of dithiothreitol (DTT), which serves to crosslink some 
of the methacrylates present in the MeHA solution. Additional stiffening comes through UV 
irradiation of a photoinitiator (Irgacure 2959) that releases free radicals which crosslink the 
remaining methacrylate groups. Using this system, the researchers were able to form hydrogels 
ranging in stiffness from ~3 kPa to ~100 kPa through addition of DTT only, and used UV-induced 
stiffening to dynamically stiffen hydrogels from ~3 kPa to ~30 kPa.  
Gillette et al.17 combined two natural polymers – collagen I and alginate – to design a 
hydrogel system that could be dynamically stiffened or softened through the addition of calcium 
chloride (CaCl) or sodium citrate, respectively. Collagen and alginate were combined to form the 
initial hydrogel within a PDMS mold placed on a glass slide; a thin aluminum oxide or cellulose 
membrane was placed over the hydrogel to allow ions to pass through, but prevents passage of 
larger alginate polymer chains. To dynamically stiffen hydrogels after the initial seeding, a 60 mM 
calcium chloride solution was pipetted onto the membrane to diffuse through to the hydrogel and 
induce crosslinking of alginate polymers. Similarly, to soften the hydrogel, a 5% w/v sodium 
citrate solution can be washed over the membrane to allow for diffusion through to the alginate 
hydrogel and chelation of the calcium crosslinking alginate polymers. 
These are but a few of the methods that researchers have employed to study how a dynamic 
ECM will impact cellular responses. While each of these methods has its own strengths and 
limitations, they, as well as others, have aided the discovery of therapeutic targets and treatment 
options to mitigate tumor progression. 
Tumors stiffen as they progress, and this presents issues for treatment options by limiting 
drug diffusion to targeted tissues and exerting environmental pressures that facilitate further 
disease progression. Potential therapeutic options that are currently being explored include use of 
collagenase, collagen18-20 or hyaluronic acid21-24 synthesis inhibitors, and integrin inhibitors25. 
These methods have traditionally been employed as a means to soften tissue and thereby increase 
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drug diffusivity; however studies focused on cell-ECM interactions also suggest that such changes 
in the cells’ microenvironment may be sufficient to transition tumor cells to a more drug sensitive 
state25,26. 
Previous studies observed how cells adapt to changes in their ECM, but the system 
developed by Stowers et al.27 is uniquely adapted to study the effects of dynamic ECM stiffness. 
Lipsomes loaded with ionic calcium and gold nanorods (20% total volume) are added to 4% 
alginate (1.6% final concentration, 40% total volume; ProNova UP MVG), 5 – 20mM calcium 
carbonate (5% total volume), cells (5% total volume), 10 – 40mM D-(+)-Gluconic acid δ-lactone 
(5% total volume), and Matrigel (25% total volume; VWR International) (as in chapter 2) then 
stimulated with NIR light to induce further hydrogel stiffening. This occurs because exposure to 
NIR light causes the gold nanorods to undergo surface plasmon resonance and heat the lipid layer 
close to its gel-to-fluid phase transition at 41°C, allowing the ionic calcium to leak out of liposomes 
and form additional cross-links with nearby alginate polymers. We therefore sought to use this 
platform to investigate our hypothesis that the physical forces from a stiffening microenvironment 
would increase breast cancer resistance to chemotherapeutic treatment. In addition, we 
hypothesized that varying the exposure time of cells to stiffened ECM would attenuate this 
stiffness-dependent drug response. The ability to dynamically stiffen the ECM surrounding breast 
cancer cell cultures in situ, without requiring cells to be removed from a specific hydrogel 
environment and reseeded in a different environment, made this alginate hydrogel system an ideal 
platform to test our hypotheses. 
3.2 MATERIALS AND METHODS 
3.2.1 Liposome preparation 
Liposomes were prepared using the interdigitation-fusion method described by Ahl et al.28. 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, Avanti, 850355P/C) was diluted in 
chloroform (Fisher Scientific, CAS: 67-66-3) at 25 mg/mL and rotary evaporation (150 mbar 
vacuum, ~60 rpm, 55 °C, 15 m) was used to coat a round-bottom flask with thin layers of lipids. 
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After 15 m incubation on the rotary evaporator, the newly formed lipid cake was placed in a 
desiccator overnight to ensure complete evaporation of any residual chloroform. The lipid cake 
was rehydrated with 2 mL ultra-pure water and placed on a rotator for 30 m to ensure hydration of 
the entire lipid cake. The solution was then sonicated via sonic probe (60% amplitude for 10 m) to 
form small unilaminar vesicles. At this point, the lipid solution was passed through a 0.22 µm filter 
(Millipore, SLGS033SB) and 424 µL of 100% ethanol (Fisher Scientific, CAS: 64-17-5) was 
added to form interdigitated sheets. Gold nanorods and 500mM calcium chloride (Sigma-Aldrich, 
C1016) was added and allowed to incubate at 55 °C for 2 hours with gentle agitation every 30 m 
to ensure encapsulation of cargo into newly forming liposomes. After incubation, a series of 
washes with 300 mM sodium chloride (Fisher Scientific, 7647-14-5) plus 1 mM HEPES (Sigma-
Aldrich, H3375) was performed to remove any free-floating nanorods or calcium. 
3.2.2 Hydrogel preparation 
Hydrogels were prepared using similar methods described in chapter 2, with the addition 
of liposomes to the gel mixture. The following were combined in the order listed, with thorough 
mixing after each new item added to the gel mixture: 4% alginate (Pronova UP MVG; 40% total 
volume, 1.6% final concentration), 5 – 20 mM CaCO3 (5% total volume), liposomes loaded 500 
mM CaCl2 plus AuNRs (20% total volume), cells (8 million – 16 million cells/mL; 5% total 
volume), 10 – 40 mM D-(+)-Gluconic acid δ-lactone (Sigma-Aldrich, G4750; 5% total volume), 
and Matrigel (VWR International, 47743-715; 25% total volume). 50 µL of the final mixture was 
pipetted into each well of a 96-well plate (Falcon, REF: 353072) and placed in an incubator (37°C, 
5% CO2) for 1 h to promote gelation. 100 µL of culture media was added to each well and cultures 
were returned to the incubator for cell growth and maintenance.  
3.2.3 Dynamic stiffening of alginate hydrogels 
Prior to exposing samples to near infrared light, all media was aspirated from each sample 
to minimize light scattering. A Lasermate (IML808-2500FLAM4A) set at 2.0 W was used to 
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irradiate samples for 45 s each. After irradiating the final sample, 100 µL of fresh culture media 
was added to each culture well and the samples were returned to the cell incubator (37 °C, 5% 
CO2) for routine growth and maintenance.  
3.2.4 Statistical analysis 
A two-tailed Student’s t-test assuming unequal variance was used to compare samples, and 
a p-value of less than 0.05 was used to determine statistical significance. Microsoft Excel Solver 
was used to fit cell viability data to a sigmoidal function to generate LD50 curves. 
3.3 RESULTS 
Cells were cultured in an alginate-Matrigel hydrogel platform, as described in Stowers et 
al.27, which uses calcium-loaded liposomes to drive cross-linking following exposure to near- 
infrared (NIR) light. Cells were initially cultured in hydrogels for 3 days to begin formation of 
spheroid micro-structures (Fig. 3.1a). Hydrogels were stiffened via NIR triggered cross-linking 
(Fig. 3.1b,c), and cells were cultured for 3 additional days before treatment with doxorubicin for 
48 h (Fig. 3.1a). MDA-MB-231 cultures that were grown in dynamically stiffened hydrogels had 
a significant decrease in sensitivity to doxorubicin for cultures that were stiffened from 450 Pa to 
1,600 Pa (LD50 = 10 µM in 450 Pa static cultures vs. LD50 = 80 µM in cultures stiffened from 50 
Pa to 1,600 Pa; p = 0.004; Fig. 3.2a) as well as those stiffened from 2,000 Pa to 3,000 Pa (LD50 
= 32 µM in 2,000 Pa static cultures vs. LD50 = 185 µM in cultures stiffened from 2,000 Pa to 
3,000 Pa, p = 0.014) compared to their static hydrogel counterparts (Fig. 3.2a). This relationship 
was not observed in MCF7 (Fig. 3.2b); there was no statistically significant difference in 
sensitivity to doxorubicin for cultures stiffened from 450 Pa to 1,600 Pa (LD50 = 6 µM in 450 Pa 
static cultures vs. LD50 = 13 µM in cultures stiffened from 450 Pa to 1,600 Pa; p = 0.143) or 2,000 
Pa to 3,000 Pa (LD50 = 12 µM in 2,000 Pa static cultures vs. LD50 = 17 µM in cultures stiffened 
from 2,000 Pa to 3,000 Pa; p = 0.492) when compared to static cultures. 
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The time between dynamic stiffening of hydrogel cultures and treatment with doxorubicin 
was varied to determine if cells undergo adaptation to stiffened ECM that may alter drug 
sensitivity. Cells were cultured in hydrogels for 3 days to allow formation of micro-structures 
before being exposed to NIR to induce dynamic stiffening. Cultures were then maintained 24, 72, 
or 120 h in the stiffened ECM before treatment with doxorubicin. Resistance to doxorubicin 
peaked in MDA-MB-231 cells that were treated 72 h post-stiffening with an LD50 of 80 µM for 
cultures stiffened from 450 to 1,600 Pa and 185 µM for cultures stiffened from 2,000 to 3,000 Pa 
(Fig. 3.2a). By 120 h post-stiffening, this increase in resistance dropped to 87 µM for cultures 
stiffened from 450 to 1,600 Pa (p = 0.323) and 71 µM for cultures stiffened from 2,000 to 3,000 
Pa (p = 0.021). We hypothesize that the stiffening from 2,000 Pa to 3,000 Pa elicits an acute 
response from MDA-MB-231 cells that results in an increased resistance to doxorubicin, which is 
shown at the 72 h acclimation time-point. However, our data suggests this response equilibrates 
by the 120 h acclimation time-point. Sensitivity of 231 to doxorubicin was greatest at 24 h post-
stiffening with LD50 measures of 5 µM for cultures stiffened from 450 to 1,600 Pa and 3 µM for 
cultures stiffened from 2,000 to 3,000 Pa. 
MCF7 cultures behaved inversely to their MDA-MB-231 counterparts (Fig. 3.2b). Peak 
resistance for MCF7 cultures was observed following 24 h acclimation in the stiff gels, with an 
LD50 of 26 µM for cultures stiffened from 450 to 1,600 Pa and 16 µM for cultures stiffened from 
2,000 to 3,000 Pa. Resistance progressively decreased to LD50 values of 13 µM (p = 0.154) and 
8 µM (p = 0.104) for cultures stiffened from 450 to 1,600 Pa and 17 µM (p = 0.834) and 7 µM (p 
= 0.072) for cultures stiffened from 2,000 to 3,000 Pa at 72 h and 120 h acclimation, respectively. 
However, when comparing across different lengths of acclimation periods, these decreases in 
resistance were not statistically significant. 
Dynamic stiffening had a significant difference for every acclimation duration tested with 
MDA-MB-231 cultures as determined by a Student’s t-test with p < 0.05 denoting significance. 
This suggests that the duration of exposure to a particular set of ECM microenvironmental stiffness 
conditions contributes to resistance to doxorubicin in these cells. 
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3.4 DISCUSSION 
Herein we describe how we used an alginate system coupled with calcium-loaded 
liposomes to simulate the stiffening of the tissue microenvironment that is observed in breast 
cancer progression. Similar to our results from chapter 2, we observed that MDA-MB-231 cells 
have increased resistance to doxorubicin following dynamic stiffening of their ECM. Slight 
increases in resistance were seen in similar MCF7 cultures, however these results were not shown 
to be statistically significant. We believe that similar mechanisms govern the stiffness-dependent 
resistance seen in dynamically stiffened hydrogels and static hydrogels, namely, those that underlie 
phenotypic expressions driving the mesenchymal and epithelial characteristics of each cell line. 
Interestingly, we found that dynamically stiffening hydrogels increased the resistance of MDA-
MB-231 cells more than just placing them in a static hydrogel of similar stiffness alone (Fig. 3.2a).  
To further investigate this effect, we varied the time between dynamically stiffening the 
hydrogel and subsequent exposure to the chemotherapeutic agent doxorubicin (Fig. 3.1a). We 
observed that MDA-MB-231 cultures were more sensitive to doxorubicin when only given 24 h 
to acclimate to the dynamically stiffened hydrogels. In sharp contrast, their resistance to 
doxorubicin peaked when given 72 h acclimation time between stiffening and drug exposure. 
MDA-MB-231 cultures given 120 h acclimation time were not as resistant to doxorubicin as the 
72 h acclimation time group, but they were still more resistant than their static hydrogel 
counterparts. Thus, we believe that there is an acute cellular response directing MDA-MB-231 
cells into a highly resistant state between 24 – 72 h post-stiffening, but that this response is at least 
partially equilibrated by 120 h post-stiffening. MCF7 cultures had the highest observed resistance 
to doxorubicin when given only 24 h acclimation time post-stiffening, however only hydrogels 
stiffened from 2,000 Pa to 3,000 Pa for 72 h and 120 h acclimation periods were found to be 
statistically significantly different for the dynamically stiffened MCF7 cultures. Given that MCF7 
cultures did not vary significantly within acclimation time groups, and only displayed small 
changes in resistance   after the 24 h acclimation point, we believe this bolsters our findings from 
chapter 2 that the MCF7 cell line does not have a stiffness-dependent response to doxorubicin. 
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3.5 CONCLUSIONS 
In this section, we have shown that the MDA-MB-231 cell line exhibits a stiffness-
dependent resistance to doxorubicin and that drug resistance is affected by the duration of time 
that cells are exposed to an environment of a particular ECM stiffness. The MCF7 cell line, on the 
other hand, was not observed to share this stiffness-dependent resistance to doxorubicin, nor was 
it shown to be significantly affected by the duration of exposure to ECM stiffness. Taken together, 
this suggests that not all breast cancer cells will be significantly affected by stiffening of their 
ECM, but some subtypes may have their resistance to doxorubicin significantly increased by the 





Fig. 3.1 – An alginate hydrogel platform was used to dynamically stiffen hydrogels to 
mimic progressive ECM stiffening. a) Cells were seeded into hydrogels and 
cultured for 3 days before dynamic stiffening with NIR light. After stiffening, 
cultures were given 1 – 5 days to acclimate to the new stiffness of the hydrogel 
before being exposed to doxorubicin for 2 days (48 h). Following treatment with 
doxorubicin, viability assays were performed to determine doxorubicin resistance. 
b) 450 Pa hydrogels were exposed to NIR light for 45 s to achieve ECM stiffness 
similar to 2,000 Pa static hydrogels. The same technique was used to stiffen 2,000 
Pa hydrogels to 3,000 Pa. c) NIR light induces surface plasmon resonance in 
encapsulated gold nanorods (gold) to heat liposomes (pink) close to their gel-to-
liquid transition temperature. This causes calcium (green) to leak from the 
liposomes and form additional alginate cross-links, thereby stiffening the hydrogel. 
The above figure was adapted from Joyce et al.26. 
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Fig. 3.2 – MDA-MB-231 cultures have an acclimation-dependent increase in resistance to 
doxorubicin.  a) MDA-MB-231 and b) MCF7 cells were cultured in hydrogels 
with an initial stiffness of 450 Pa or 2,000 Pa for 3 days. On day 3, hydrogels either 
remained static (450 Pa or 2,000 Pa) or were stiffened (450 -> 1,600 Pa or 2,000 -> 
3,000 Pa) using NIR light. Samples were then given 24 h to 120 h to acclimate to 
the hydrogel stiffness before 48 h treatment with doxorubicin. MDA-MB-231 cells 
showed a higher resistance to doxorubicin as hydrogel stiffness increased and this 
stiffness-dependent resistance was found to be partially dependent on duration of 
exposure to hydrogel stiffness. Comparable MCF7 samples did not show any 
significant change in resistance to doxorubicin across hydrogel stiffness or 
acclimation time. The above figure was adapted from Joyce et al.26. *p-value < 
0.01; **p-value < 0.02; ***p-value < 0.03; NS = not significant, p-value >0.05 
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Chapter 4: Molecular Characterization of Breast Cancer Cells Cultured in 
Soft and Stiff Hydrogels4 
4.1 INTRODUCTION 
Metastasis complicates disease treatment and decreases patient survivability, as the spread 
of tumors presents new locations that must be treated and these new locations will have different 
microenvironments that can influence resistance to treatment. Tumor metastasis occurs when cells 
from the primary tumor migrate to new locations and establish tertiary tumors. This process has 
been intensely studied in hopes of discovering methods to prevent or reduce the disease spreading 
through a patient’s body. For breast cancer cells, this process has been well characterized (see1-3 
for more thorough reviews on the subject). Generally speaking, cells from a primary breast tumor 
will transition to a state where they are much more motile in a process called Epithelial-to-
Mesenchymal transition (EMT). This transition is characterized by a loss of cell-cell adhesions, 
change from cuboidal to spindle shape, and increased expression of genes facilitating cell 
migration. For breast cancer, there have been six critical pathways identified that drive EMT: TGF-
β (transforming growth factor- β), Wnt, Notch, Hippo, Hedgehog, and receptor tyrosine kinase 
pathways2. Our studies focused on three of these such pathways which are known to play a 
significant role in breast cancer initiation and metastasis. 
TGF-β is a secreted protein that regulates key cellular processes including apoptosis, 
proliferation, and differentiation4. In very early stages of tumor development TGF-β signaling 
functions as a tumor suppressor, but as the disease progresses the TGF-β pathway has been shown 
to support tumor growth and metastasis through the induction of EMT5. Secreted TGF-β will bind 
to cell surface receptors and form complexes with Smad proteins which, when phosphorylated, 
                                                 
4 Portions of this chapter were adapted from M. H. Joyce, C. Lu, E. R. James, R. Hegab, S. C. Allen, L. J. Suggs and 
A. Brock, "Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to 
Doxorubicin," Front Oncol, vol. 8, p. 337, 2018. A. B. and M. J. were responsible for the planning of the study and 
writing of the manuscript; C. L., E. J., M. J., R. H., and S. A.conducted the experiments; all authors were involved 
with the analysis of the manuscript. 
Portions of this chapter include data that is currently in preparation for publication. 
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will translocate to the nucleus to drive transcription of target genes such as ZEB1/2, SNAI1/2, and 
TWIST1.  
The Wnt pathway drives EMT through the downregulation of E-cadherin and up-regulation 
of Snail (SNAI1)6, SLUG (SNAI2)7, and TWIST8 transcription factors. This can occur through the 
canonical β-catenin dependent pathway9 or the non-canonical planar cell polarity and Wnt/Ca2+ 
pathways10. DiMeo et al. highlighted the necessity of Wnt signaling in EMT by demonstrating that 
over-expression of DKK1 (negative regulator of the Wnt pathway) was sufficient to decrease 
tumor formation in mice and reduce expression of EMT markers Slug and Twist11. A study of 158 
invasive breast cancer samples showed that 99% of the samples examined had alterations in at 
least one antagonist Wnt pathway, further highlighting its clinical significance as a therapeutic 
target12. 
The Hippo pathway is a tumor suppressor pathway that contributes to tissue growth, 
differentiation, and regeneration. Yes-associated protein (YAP) and tafazzin (TAZ) are two 
oncogenes that make up part of the core transcriptional components, and both are highly regulated 
by the Hippo pathway. Phosphorylation of YAP/TAZ by LATS1/2 kinase suppresses their activity 
by causing them to accumulate in the cytoplasm of the cell where they undergo proteasome 
degradation13. Activation and subsequent nuclear translocation of YAP/TAZ due to inactivation 
of the Hippo pathway has been shown to lead to EMT14-16 and increased proliferation17-19. Recent 
work has described how YAP/TAZ activation is mediated by the stiffness of their ECM through 
JNK20-22, RHO23,24, and integrin-mediated adhesion pathways23,25,26. Given cells in the mammary 
gland are already sensitive to ECM stiffness, they are an ideal platform to study YAP/TAZ induced 
EMT27-29. 
In this chapter, we sought to molecularly characterize the changes that occur when 
culturing mammary adenocarcinoma cells in soft (450 Pa) and stiff (2,000 Pa) ECM. Our studies 
focused on changes in markers of EMT due to recent findings that have found links between cells 
that have undergone EMT and increased chemoresistance in different tumor types. 
 64 
4.2 MATERIALS AND METHODS 
4.2.1 Staining for EMT markers 
Samples were fixed with a 15 min. exposure to 4% paraformaldehyde at room temperature. 
Blocking and permeabilization buffer (0.1% Triton X-100 and 1% bovine serum albumin [BSA] 
diluted in 1xPBS) was added to each sample and incubated at room temperature for 1 h. Following 
this, samples were incubated with primary antibody against YAP (Santa Cruz, sc-101199) or actin 
(Phalloidin488, Thermofisher, A12379) for 1 h at room temperature. Cell nuclei were stained with 
300 nM DAPI (ThermoFisher, D1306) for 30 m at room temperature before being imaged on a 
Zeiss confocal or EVOS epifluorescent microscope. 
4.2.2 Quantitative real-time PCR 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, 74104, Hilden, Germany) 
and was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, 4368814) according to the manufacturer’s instructions. Quantitative PCR was 
performed using the PowerUp SYBR Green Master Mix (Applied Biosystems, A25743) with 20 
ng cDNA input in 20 µl reaction volume run on a ViiA7 Real-Time PCR system (Applied 
Biosciences). B2M (beta-2-microglobulin) expression level was used for normalization as a 
housekeeping gene. The primers for beta-2-microglobulin (HK-B2M), Vimentin (VHPS-9912; 
Vimentin), and CDH1 (VHPS-1738; E-Cadherin) were designed and synthesized by 
RealTimePrimers.com (www.realtimeprimers.com). Delta CT (ΔCT) values for each sample were 
first normalized to the B2M house-keeping gene, and expression levels were analyzed pair-wise 
comparing samples cultured in 2,000 Pa hydrogels to the same cell type cultured in 450 Pa 
hydrogels. 
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4.2.3 Statistical Analysis and Mathematical Modeling 
A two-tailed Student’s t-test assuming unequal variance was used to compare samples, and 
a p-value of less than 0.05 was used to determine statistical significance. MatLab was used for plot 
generation and curve fitting.  
 
4.3 RESULTS 
4.3.1 Expression of EMT Markers 
Quantitative real-time PCR was performed using a panel of well-known markers of EMT 
to evaluate how stiffness of the ECM would affect MDA-MB-231 and MCF7 cell state (Fig. 4.1a). 
We found that expression of E-Cadherin was decreased in both MDA-MB-231(p = 0.037) and 
MCF7 (p = 0.120) cells cultured in 2,000 Pa hydrogels versus their 450 Pa counterparts (Fig. 4.1b), 
however only the MDA-MB-231 cells showed a statistically significant difference in expression 
with hydrogel stiffness. Decreased expression of E-Cadherin is a well-known marker of EMT, thus 
further supporting our findings that the stiffer hydrogels promote transition towards a 
mesenchymal phenotype. MCF7 cells cultured on 2,000 Pa hydrogels showed an increase in 
SNAIL1 (p = 0.069, Fig. 4.1c) and SLUG (p = 0.006, Fig. 4.1d) with a decrease in ZEB1 (p = 
0.445, Fig. 4.1e) and vimentin (p = 0.004, Fig. 4.1f) expression compared to similar cultures grown 
in 450 Pa hydrogels. MDA-MB-231 samples cultured in 2,000 Pa hydrogels showed a decrease in 
all SNAIL1 (p = 0.001, Fig. 4.1c), SLUG (p = 0.017, Fig. 4.1d), ZEB1 (p = 0.002, Fig. 4.1e), and 
vimentin (p = 0.018, Fig. 4.1f) additional markers tested when compared to their 450 Pa 
counterparts. 
We took the same data and normalized all samples to the epithelial model (MCF7) cultured 
on the softest stiffness (450 Pa) (Fig. 4.2a). What we found was that there were significant 
differences in expression between our mesenchymal (MDA-MB-231) and epithelial (MCF7) cell 
models for all genes tested. Expression of E-Cadherin was much higher in MCF7 cultures and 
culturing the highly epithelial MCF7 cells in 2,000 Pa hydrogels was not sufficient to decrease 
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their expression of E-Cadherin to similar levels seen in MDA-MB-231 cells cultured in either 450 
Pa (p = 0.002) or 2,000 Pa (p = 0.002) hydrogels (Fig. 4.2b). SNAIL1 expression was also found 
to be higher in MCF7 cultures compared to MDA-MB-231 (p = 0.002 for 450 Pa and p = 0.0002 
for 2,000 Pa hydrogels, Fig. 4.2c). SLUG (p = 0.0003 for 450 Pa and p = 0.002 for 2,000 Pa 
hydrogels, Fig. 4.2d), ZEB1 (p = 0.0004 for 450 Pa and p = 0.0001 for 2,000 Pa hydrogels, Fig. 
4.2e), and Vimentin (p = 0.0005 for 450 Pa and p = 0.0001 for 2,000 Pa hydrogels, Fig. 4.2f) all 
had higher overall expression in MDA-MB-231 cultures and were found to decrease with 
expression (p = 0.017 for SLUG, p = 0.002 for ZEB1, p = 0.018 for vimentin) as stiffness 
increased. SLUG was shown to increase with stiffness (p = 0.006, Fig. 4.2d) for MCF7 cultures, 
but expression of ZEB1 (Fig. 4.2e) and vimentin (Fig. 4.2f) did not show a statistically significant 
difference between 450 Pa and 2,000 Pa cultures.  
4.3.2 Increasing hydrogel stiffness leads to nuclear localization of YAP 
Samples grown on 450 or 2,000 Pa hydrogels were stained with YAP antibodies as a 
marker of mesenchymal phenotype. High levels of YAP nuclear localization confirmed that 231 
cultures (Fig. 4.3a) exhibited higher markers of mesenchymal phenotype than their MCF7 (Fig. 
4.3b) counterparts. The mean fluorescent intensity (MFI) of YAP-labeled nuclei was MFI = 930 
a.u. in 231 cells cultured in 450 Pa hydrogels and MFI = 2,030 a.u. for the same cells cultured in 
2000 Pa hydrogels. Given the 231 cells grown on 2,000 Pa hydrogels showed higher levels of YAP 
nuclear localization than similar cultures on 450 Pa hydrogels (p = 1.36E-22), we believe that a 
stiffer ECM promotes the mesenchymal phenotype for these cells. Similar findings were observed 
in MCF7 cultures, but to a much lesser extent (MFI = 22 a.u. for cells cultured in 450 Pa hydrogels 
and MFI = 28 a.u. for cells cultured in 2,000 Pa hydrogels, p = 0.0001).  
4.3.3 Mathematical models suggests stiffness-induced resistance to doxorubicin is not fully 
explained by changes in proliferation rates 
MDA-MB-231 cells expressing nuclear localized red fluorescent protein were cultured in 
450 Pa, 900 Pa, 1,400 Pa, or 2,000 Pa hydrogels (n = 11 for all groups) seeded in a 96-well plate 
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and imaged every 4 h to track cell growth. Cells were cultured for 6 days to collect growth 
dynamics data (Fig. 4.4). All cultures were then exposed to 10 µM doxorubicin for 48 h, before 
the drug was replaced with standard growth medium and monitored for an additional 5 days (11 
d, 262 h total, Fig. 4.5). Growth trajectories (geff) were calculated by fitting cell count data from 
time points 48 h – 152 h to a single exponential growth model (Fig. 4.6a,b). Post-treatment growth 
trajectories (keff) were calculated similarly, by fitting cell count data from time points 152 h – 262 
h to a single exponential death model (Fig. 4.6a,b). Our results from this show that the growth rate 
of MDA-MB-231 cells is inversely correlated with hydrogel stiffness (Fig. 4.6c). Using the same 
data, we modeled how sensitivity to doxorubicin would be affected by a two-population model 
that accounted for cells expressing both the epithelial and mesenchymal phenotype with the option 
to transition between the two states (Fig. 4.7a). Here we set the mesenchymal growth rate (gm = 
0.0013 cells per hour) and the transition from mesenchymal-to-epithelial rate (kme = 0.0013) to 
allow us to fit for the epithelial growth rate (ge = 0.0335) and transition rate from epithelial-to-
mesenchymal phenotype (kem) (Fig. 4.7b). Our model showed that the transition rate from 
epithelial-to-mesenchymal phenotype (kem) increased with hydrogel stiffness (Fig. 4.7c). We were 
then able to calculate drug sensitivity (Fig. 4.8a) by fitting the equations shown in Fig. 4.8b to 
find the average death rate (dE and dM) of each phenotype following treatment with doxorubicin. 
Our results show that cells expressing the epithelial phenotype are more sensitive to doxorubicin 
than cells expressing a mesenchymal phenotype (Fig. 4.8c). 
4.4 DISCUSSION 
Previous studies have shown links between EMT and increased resistance to certain 
chemotherapeutics. We sought to see if this was true for breast cancer cells treated with 
doxorubicin, a drug with clinical relevance to this disease known to induce chemotherapeutic 
resistance. To this end, we cultured breast cancer cells known to exhibit the epithelial (MCF7) and 
mesenchymal (MDA-MB-231) phenotypes in hydrogels that mimicked the stiffness of ECM 
ranging from healthy mammary tissue (450 Pa) to early stage breast tumor (2,000 Pa). Using 
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quantitative real-time PCR, we found that SNAIL1 and SLUG increase with ECM stiffness in 
MCF7 cells, but ZEB1 and vimentin decrease with ECM stiffness. This, paired with the fact that 
expression of all markers examined decreased for MDA-MB-231 cells, suggests that matrix 
stiffness alone may not be sufficient to fully induce EMT in certain breast cancer cells. Both cell 
lines showed loss of cell-cell adhesions, and MCF7 cells upregulated expression of additional 
negative regulators of E-cadherin (SNAIL1 and SLUG). However, neither MDA-MB-231 nor 
MCF7 cells showed increased expression of ZEB1 or vimentin. ZEB1 has recently been shown to 
induce chemoresistance in breast cancer cells through activation of ataxia-telangiectasia mutated 
(ATM) kinase30, however our results suggest that this is not the mechanism governing the stiffness-
dependent resistance seen in the MDA-MB-231 samples. 
A recent study looking at partial EMT in pancreatic ductal adenocarcinoma (PDAC), breast 
cancer, and colorectal cancer cell lines showed that cells classified as having undergone partial 
EMT did not always show a significant decrease in expression of E-cadherin, rather they re-
localized it from the membrane to the interior of the cell31. Knowing this, we turned our attention 
to another marker of EMT – nuclear localization of YAP. YAP nuclear localization and subsequent 
loss of E-cadherin are classical markers of cells undergoing EMT, so we cultured MCF7 and 
MDA-MB-231 cells in 450 Pa and 2,000 Pa to examine how ECM stiffness would affect YAP 
nuclear localization. We found that both cell lines showed higher nuclear localization of YAP 
when cultured in stiffer hydrogels. Similar findings were found by Rice et al.32 in pancreatic ductal 
adenocarcinoma cells grown in hydrogels of increasing stiffness. Thus, this further supports our 
hypothesis that ECM stiffness increases breast cancer cell resistance to doxorubicin through partial 
induction of EMT.  
4.5 CONCLUSION 
We found that quantitative analysis of EMT-associated gene expression suggests that ECM 
stiffness alone is not sufficient to induce MCF7 cells to fully undergo EMT or to prompt further 
EMT in MDA-MB-231 cells. Our results find that the decreased expression of ZEB1 in MDA-
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MB-231 cells suggests that the stiffness-dependent resistance these cells displayed in chapter 2 
and chapter 3 is likely not due to ZEB1 activation of ATM. Mathematical modeling of MDA-MB-
231 response to doxorubicin points towards a link between EMT rate and ECM stiffness as the 




Fig. 4.1 – Expression of EMT markers suggests ECM stiffness promotes hybrid cell state in 
MDA-MB-231 and MCF7 cells. a) The expression of five EMT-related genes was examined 
in MDA-MB-231 (231)/MCF7 cells cultured in 450 Pa vs 2,000 Pa hydrogels using quantitative 
PCR (qPCR). Cells were cultured in hydrogels for 6 days before RNA was isolated from samples 
and prepared for qPCR. All primers were normalized to the beta-2-microglobulin (B2M) house-
keeping gene. b) E-cadherin expression was shown to decrease when both cell lines were cultured in 
2,000 Pa hydrogels vs 450 Pa hydrogels, though only the MDA-MB-231 (p = 0.037) cultures 
showed a significant decrease whereas the MCF7 (p = 0.120) cultures did not. c) SNAIL1 expression 
was shown to significantly decrease for MDA-MB-231 samples (p = 0.001), and while expression 
increased in MCF7 cultures (p = 0.069) it was not found to be statistically significant. d) Expression 
of SLUG (SNAI2) was shown to significantly decrease for MDA-MB-231 cultures (p = 0.017), but 
increase 3-fold for MCF7 cultures (p = 0.006). e) ZEB1 was shown to have less expression in MDA-
MB-231 cells (p = 0.002), but were not shown to be statistically different for MCF7 cells (p = 0.445) 
cultured in stiffer hydrogels. f) Expression of vimentin was found to be significantly decreased for 
both MDA-MB-231 (p = 0.018) and MCF7 (p = 0.004) cells cultured in 2,000 Pa hydrogels 
compared to their counterparts cultured in 450 Pa hydrogels. 
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Fig. 4.2 – Expression of EMT markers compared to epithelial cells on soft hydrogels. a) The 
expression of five EMT-related genes was examined in MDA-MB-231 (231)/MCF7 
cells cultured in 450 Pa vs 2,000 Pa hydrogels using quantitative PCR (qPCR). All 
primers were normalized to the beta-2-microglobulin (B2M) house-keeping gene 
and compared against the MCF7 cells cultured in 450 Pa hydrogels. b) E-cadherin 
expression is much higher in MCF7 cells for both 450 Pa (p = 0.007) and 2,000 Pa 
(p = 0.002) hydrogels. c) SNAIL1 expression overall is much lower in MDA-MB-
231 cultures (p = 0.002 for 450 Pa and p = 0.0002 for 2,000 Pa hydrogels). SNAIL1 
further decreases in MDA-MB-231 cultures (p = 0.001) as stiffness increases but 
increases with stiffness in MCF7 cultures (p = 0.069). d) Expression of SLUG 
(SNAI2) is much higher in MDA-MB-231 cultures (p = 0.0003 for 450 Pa and p = 
0.002 for 2,000 Pa hydrogels). Again, SLUG further decreases in MDA-MB-231 
cultures (p = 0.017) as stiffness increases but increases with stiffness in MCF7 
cultures (p = 0.006). e) ZEB1 expression is much higher in MDA-MB-231 cultures 
overall (p = 0.0004 for 450 Pa and p = 0.0001 for 2,000 Pa hydrogels). Here we 
observe a stiffness-dependent decrease in ZEB1 for both MDA-MB-231 (p = 0.002) 
and MCF7 (p = 0.445), though differences in MCF7 cultures were not found to be 
statistically significant. f) Vimentin is dramatically more expressed in MDA-MB-
231 cultures (p = 0.0005 for 450 Pa and p = 0.0001 for 2,000 Pa hydrogels). A 
stiffness-dependent decrease in vimentin was observed in both MDA-MB-231 (p = 




Fig. 4.3 – Stiffer ECM increases nuclear localization of YAP and decreases expression of E-
Cadherin. a) MDA-MB-231 and b) MCF7 cells were cultured on 450 Pa or 2,000 
Pa hydrogels for 3 days before fixation and staining with YAP (red) and actin 
(phalloidin-488, green) antibodies, as well as DAPI (blue). Images were captured 
using confocal microscopy and analysis was done in ImageJ to determine nuclear 
localization of YAP (n = 123 for MDA-MB-231 cells cultured in 450 Pa hydrogels, 
n = 119 for MDA-MB-231 cells cultured in 2,000 Pa hydrogels, n = 72 for MCF7 
cells cultured in 450 Pa hydrogels, n = 90 for MCF7 cells cultured in 2,000 Pa 
hydrogels). There is a stiffness-dependent increase in nuclear localization of YAP 
for both MDA-MB-231 (p = 1.38E-22) and MCF7 (p = 0.02) cultures, though the 
increase in MCF7 cultures is small. MDA-MB-231 cultures showed significantly 
higher expression of nuclear YAP compared to similar MCF7 cultures (p = 2.37E-
37 for 450 Pa and p = 4.44E-46 for 2,000 Pa). Scale bar = 50 µm. *p-value < 0.05; 
****p-value << 0.001 
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Fig. 4.4 – Growth dynamics of MDA-MB-231 cells in hydrogels of varying stiffness before 
treatment with doxorubicin. MDA-MB-231 cells were seeded into 450 (green), 
900 (cyan), 1400 (blue), or 2000 (pink) Pa hydrogels and cultured for 6 days in an 
Incucyte S3 incubator. Images were collected every 4 h and cells were counted 
using the S3 on-board software.  
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Fig. 4.5 – Growth dynamics of MDA-MB-231 cells in hydrogels of varying stiffness 
following treatment with doxorubicin. Following 6 days of standard growth in 
450 (green), 900 (cyan), 1400 (blue), or 2000 (pink) Pa hydrogels, cells were 
exposed to 10 µM doxorubicin for 48 h. Cultures were monitored for an additional 
5 days to collect growth dynamics information following treatment with 
doxorubicin. Images were collected every 4 h in an Incucyte S3 incubator and cells 
were counted using the S3 on-board software.  
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Fig. 4.6 – Proliferation rate of MDA-MB-231 cells decreases with increased hydrogel 
stiffness. a) Data collected between 48 h and 152 h time points was fit to b) a single 
exponential growth model to calculate the effective growth rate for cultures pre-
treatment. The cell count data from 152 h to 262 h time points, was fit to a single 
exponential death model to calculate the effective growth rate of cells following 48 
h exposure to doxorubicin. c) Our results show that growth rate of MDA-MB-231 
cells decreases as the stiffness of the hydrogel increases. The error bars shown 
represent the 95% confidence interval, n = 5 for each hydrogel stiffness. 
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Fig. 4.7 – Fitting data to a two-population EMT model shows rate of EMT increases with 
hydrogel stiffness. a) Growth data collected from the Incucyte S3 was fit to a two-
population model that assumed populations of epithelial (E) and mesenchymal (M) 
were present and that they could transition from one E to M (kEM) or vice-versa 
(kME). b) Assuming a mesenchymal growth rate (gM) of 0.0013 cells per hour and 
kME of 0.0013, we fit the data to calculate epithelial growth rate (gE) and kEM. c) 
Our mathematical model shows that the rate of transition from E to M (kEM or 
EMT) increases with hydrogel stiffness. 
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Fig. 4.8 – Cells with mesenchymal phenotype have a lower death rate in response to 
treatment with doxorubicin. a) We fit our data to the equations in b) using 
previously calculated variables to determine the sensitivity of epithelial (E) and 
mesenchymal (M) populations to doxorubicin. c) Our model shows that 
mesenchymal cells are more resistant to doxorubicin. This suggests that cells 
undergoing transitioning from E to M (kEM or EMT) would have a survival 
advantage and increase the overall resistance of the cell entire population. 
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Table A1 – Doxorubicin sensitivity for MCF7 and 231 across culture conditions. Dose 
response curves of 231 and MCF7 cells cultured in static hydrogels, dynamic 
hydrogels, and monolayer culture conditions following 48h exposure to 





Fig. A1 – Exposure to Near Infrared (NIR) light does not significantly affect response to 
doxorubicin. MDA-MB-231 cells were cultured as a monolayer (2D) on tissue 
culture plastic before being exposed to NIR light for 45 s. Samples were cultured an 
additional 2 days after lasing prior to treatment with doxorubicin. Staining with 
acridine orange/propidium iodide (AOPI) was used to quantify the ratio of live/dead 
cells. a) Cells that were exposed to NIR light did not show a significant difference 
(p = 0.064) in resistance to doxorubicin compared to b) control samples that were 
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